Literature DB >> 24114957

Phase I design for completely or partially ordered treatment schedules.

Nolan A Wages1, John O'Quigley, Mark R Conaway.   

Abstract

The majority of methods for the design of phase I trials in oncology are based upon a single course of therapy, yet in actual practice, it may be the case that there is more than one treatment schedule for any given dose. Therefore, the probability of observing a dose-limiting toxicity may depend upon both the total amount of the dose given, as well as the frequency with which it is administered. The objective of the study then becomes to find an acceptable combination of both dose and schedule. Past literature on designing these trials has entailed the assumption that toxicity increases monotonically with both dose and schedule. In this article, we relax this assumption for schedules and present a dose-schedule finding design that can be generalized to situations in which we know the ordering between all schedules and those in which we do not. We present simulation results that compare our method with other suggested dose-schedule finding methodology.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  continual reassessment method; dose-finding studies; maximum tolerated dose; partial ordering; phase I trials; treatment schedules

Mesh:

Substances:

Year:  2013        PMID: 24114957      PMCID: PMC3947103          DOI: 10.1002/sim.5998

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  11 in total

1.  Non-parametric optimal design in dose finding studies.

Authors:  John O'Quigley; Xavier Paoletti; Jean Maccario
Journal:  Biostatistics       Date:  2002-03       Impact factor: 5.899

2.  Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Authors:  Marcos de Lima; Sergio Giralt; Peter F Thall; Leandro de Padua Silva; Roy B Jones; Krishna Komanduri; Thomas M Braun; Hoang Q Nguyen; Richard Champlin; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2010-07-29       Impact factor: 6.860

3.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

4.  Determining a maximum-tolerated schedule of a cytotoxic agent.

Authors:  Thomas M Braun; Zheng Yuan; Peter F Thall
Journal:  Biometrics       Date:  2005-06       Impact factor: 2.571

5.  Dose-finding design for multi-drug combinations.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Clin Trials       Date:  2011-06-07       Impact factor: 2.486

6.  Continual reassessment method for partial ordering.

Authors:  Nolan A Wages; Mark R Conaway; John O'Quigley
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

7.  A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies.

Authors:  Carlos Graux; Anne Sonet; Johan Maertens; Justus Duyster; Jochen Greiner; Yves Chalandon; Giovanni Martinelli; Dagmar Hess; Dominik Heim; Francis J Giles; Kevin R Kelly; Athos Gianella-Borradori; Blandine Longerey; Ekaterine Asatiani; Narmyn Rejeb; Oliver G Ottmann
Journal:  Leuk Res       Date:  2013-06-05       Impact factor: 3.156

8.  Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.

Authors:  Yisheng Li; B Nebiyou Bekele; Yuan Ji; John D Cook
Journal:  Stat Med       Date:  2008-10-30       Impact factor: 2.373

9.  Simultaneously optimizing dose and schedule of a new cytotoxic agent.

Authors:  Thomas M Braun; Peter F Thall; Hoang Nguyen; Marcos de Lima
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

10.  Model calibration in the continual reassessment method.

Authors:  Shing M Lee
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

View more
  9 in total

1.  Performance of toxicity probability interval based designs in contrast to the continual reassessment method.

Authors:  Bethany Jablonski Horton; Nolan A Wages; Mark R Conaway
Journal:  Stat Med       Date:  2016-07-19       Impact factor: 2.373

2.  Designs for phase I trials in ordered groups.

Authors:  Mark R Conaway; Nolan A Wages
Journal:  Stat Med       Date:  2016-09-14       Impact factor: 2.373

3.  Phase I/II adaptive design for drug combination oncology trials.

Authors:  Nolan A Wages; Mark R Conaway
Journal:  Stat Med       Date:  2014-01-28       Impact factor: 2.373

4.  Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics.

Authors:  Emma Gerard; Sarah Zohar; Hoai-Thu Thai; Christelle Lorenzato; Marie-Karelle Riviere; Moreno Ursino
Journal:  Biometrics       Date:  2021-02-18       Impact factor: 1.701

5.  A benchmark for dose-finding studies with unknown ordering.

Authors:  Pavel Mozgunov; Xavier Paoletti; Thomas Jaki
Journal:  Biostatistics       Date:  2022-07-18       Impact factor: 5.279

6.  Design considerations for early-phase clinical trials of immune-oncology agents.

Authors:  Nolan A Wages; Cody Chiuzan; Katherine S Panageas
Journal:  J Immunother Cancer       Date:  2018-08-22       Impact factor: 13.751

7.  Phase I dose-escalation oncology trials with sequential multiple schedules.

Authors:  Burak Kürsad Günhan; Sebastian Weber; Abdelkader Seroutou; Tim Friede
Journal:  BMC Med Res Methodol       Date:  2021-04-14       Impact factor: 4.615

8.  Extending the Continual Reassessment Method to accommodate step-up dosing in Phase I trials.

Authors:  Thomas M Braun; Francois Mercier
Journal:  Stat Med       Date:  2022-06-05       Impact factor: 2.497

9.  Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens.

Authors:  Emma Gerard; Sarah Zohar; Christelle Lorenzato; Moreno Ursino; Marie-Karelle Riviere
Journal:  Stat Med       Date:  2021-07-14       Impact factor: 2.497

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.